NEW YORK, July 28 (GenomeWeb News) - Sirna Therapeutics said this week that it has signed an exclusive, four-year deal to manufacture all of Archemix's aptamers used through phase IIa clinical development. Sirna has additionally granted a worldwide, non-exclusive, perpetual license to its aptamer manufacture and commercialization intellectual property to Archemix.
The arrangement, said Sirna, follows an October 2003 deal under which Sirna manufactured Archemix's anti-thrombin aptamer, ARC183, for development up through phase IIa testing.
"Sirna's mission is to develop nucleic acid therapeutics based on RNA interference," Sirna senior vice president and COO Nassim Usman said in a statement. "Through our partnership and licensing agreement with Archemix ... Sirna will generate revenues as Archemix develops and commercializes its aptamer products."